パニック障害に対するHB-1の有効性と安全性:多施設共同、無作為化、二重盲検、プラセボ対照試験
The purpose of this study is to determine the safety and efficacy of HB-1, versus placebo and two monotherapies, in male and female adult patients aged 18 to 65 years, inclusive, with Panic Disorder.
調査の概要
状態
詳細な説明
This is a multicenter, randomized, double-blind, placebo-controlled trial. All patients with Panic Disorder, with or without specified co-morbidities, who meet all of the inclusion and none of the exclusion criteria will be eligible. Patients and researchers will be blinded to their treatment group.
The study will enroll approximately 240 (up to 600) adult patients who meet the diagnosis of panic disorder.
Patients will be treated for 12 weeks followed by a safety follow up visit one week after their last dose of study treatment.
研究の種類
入学 (実際)
段階
- フェーズ2
連絡先と場所
研究場所
-
-
Australian Capital Territory
-
Canberra、Australian Capital Territory、オーストラリア、2617
- Paratus Clinical Research Canberra
-
-
New South Wales
-
Blacktown、New South Wales、オーストラリア、2148
- Paratus Clinical Research Western Sydney
-
Charlestown、New South Wales、オーストラリア、2290
- Novatrials
-
Darlinghurst、New South Wales、オーストラリア、2010
- East Sydney Doctors
-
Darlinghurst、New South Wales、オーストラリア、2010
- Momentum Clinical Research Darlinghurst
-
Miranda、New South Wales、オーストラリア、2228
- Canopy Clinical Sutherland
-
Waitara、New South Wales、オーストラリア、2077
- Innovate Clinical Research
-
Westmead、New South Wales、オーストラリア、2145
- Westmead Hospital
-
Wollongong、New South Wales、オーストラリア、2500
- Canopy Clinical Wollongong
-
-
Queensland
-
Herston、Queensland、オーストラリア、4006
- Paratus Clinical Research Brisbane
-
Mackay、Queensland、オーストラリア、4740
- Mackay Hospital and Health Service
-
-
South Australia
-
Adelaide、South Australia、オーストラリア、5000
- South Australian Health and Medical Research Institute
-
-
Victoria
-
Carlton、Victoria、オーストラリア、3053
- NeuroCentrix
-
Frankston、Victoria、オーストラリア、3199
- Peninsula Therapeutic and Research Group
-
Melbourne、Victoria、オーストラリア、3004
- Ramsay Clinic Albert Road
-
Melbourne、Victoria、オーストラリア、3004
- Multidisciplinary Alfred Psychiatry Research Clinic
-
Northcote、Victoria、オーストラリア、3070
- Paratus Clinical Research Melbourne
-
Torquay、Victoria、オーストラリア、3228
- Clinical Trials Institute
-
-
Western Australia
-
West Perth、Western Australia、オーストラリア、6005
- Clinitrials
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Male or female aged 18 to 65 years old, inclusive, at the time of informed consent.
- Meets Diagnostic and Statistical Manual of Mental Disorders 5th Edition (DSM-V) Criteria for Panic Disorder.
- Minimum of one full, unexpected panic attack in week prior to screening (via Diagnostic and Statistical Manual of Mental Disorders 5th edition [DSM-V] based structured interview).
- Medically stable on current medication regimen for at least 3 months (including as needed [PRN] medications), as determined by Investigator.
- Willing to remain on current doses of other psychiatric medications throughout the length of the trial.
- Willing and able to safely stop / avoid any of the following prior to study trial: Inhibitors or inducers of CYP3A4 (grapefruit juice, erythromycin, ritonavir, telithromycin, rifampin), HMG-CoA Reductase Inhibitors (Simvastatin, Lovastatin, Atorvastatin), Beta Blockers (Timolol eyedrops, Metoprolol), Neuromuscular Blocking Agents (curare-like and depolarizing), Antihypertensive Agents (Prazosin and vasodilators, angiotensin-converting enzyme inhibitors, diuretics, beta blockers), Inhalation Anesthetics, Disopyramide, Flecainide, Quinidine, Cimetidine, Lithium, Carbamazepine, Phenobarbital, Cyclosporine, Digitalis, Aliskiren, Ramipril and Ramiprilat, aspirin, propranolol.
- Willing and able to safely stop / avoid sensitive P-glycoprotein inhibitors.
- Willing to take HB-1, telmisartan, verapamil, or placebo.
- Willing and able to provide informed consent indicating an understanding of the requirements of the study and a willingness to comply with scheduled visits and all study procedures.
- Female subjects must be surgically sterile (or have a monogamous partner who is surgically sterile) or be at least 2 years postmenopausal or commit to use 2 acceptable forms of birth control (defined as the use of an intrauterine device, a barrier method with spermicide, condoms, any form of hormonal contraceptives, or abstinence) for the duration of the study and for 4 months following the last dose of study treatment. Male subjects must be sterile (biologically or surgically) or commit to the use of a reliable method of birth control (condoms ± spermicide) for the duration of the study and for 4 months following the last dose of study treatment. Individuals who are involved exclusively in same-sex relationships are exempt from the birth control requirements but must agree to abide by the recommendations if they do engage in a heterosexual relationship.
- Female subjects who are women of childbearing potential (WOCBP) must have a negative pregnancy test at Screening, within 7 days of dosing with study treatment.
Exclusion Criteria:
- Any concomitant disease, condition, or treatment that could interfere with the conduct of the study, or that would, in the opinion of the Investigator or Sponsor, pose an unacceptable risk to the participant in the study or interfere with the interpretation of study data.
- Concurrent treatment with benzodiazepines (e.g. alprazolam, diazepam, clonazepam, lorazepam) as assessed by clinical interview and urine toxicology testing.
- Severe Agoraphobia (Panic Disorder Symptom Severity Scale (PDSS) Item 4 "agoraphobic fear/avoidance" > 2).
- Severe Generalized Anxiety (Hamilton Anxiety Rating Scale [HAM-A] Total Score > 23).
- Prior lifetime history of suicide attempt, Columbia Suicide Severity Rating Scale (C-SSRS) ≥ 4 in the past 6 months or prior lifetime history of hospitalization for depression.
- Diagnosis of Substance Use Disorder, Obsessive-Compulsive Disorder (OCD), Bipolar I, Bipolar II disorder or schizoaffective or other psychotic disorders (per Structure Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders 5th Edition (DSM-V) [SCID-V].
- Severe uncontrolled cardiac disease within 6 months of Screening, including but not limited to uncontrolled hypertension, hypotension (defined as below 90/60); unstable angina; myocardial infarction (MI) or cerebrovascular accident (CVA).
- Any clinically significant electrocardiogram (ECG) abnormalities at screening.
- Inadequate hepatic function defined as total bilirubin > 1.5 × the upper limit of normal (ULN) ranges of each institution, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) > 3 × the ULN range of each institution.
- Inadequate renal function defined as serum creatinine > 1.5 × the upper limit of normal (ULN) range of each institution and/or estimated glomerular filtration rate (eGFR) < 60.
- Any clinically significant abnormalities in clinical laboratory assessments as assessed by the Investigator.
- Any other systemic conditions or organ abnormalities that in the opinion of the Investigator may interfere with the conduct and/or interpretation of the current study.
- Unable to complete neuropsychological testing.
- Already on treatment with either telmisartan or verapamil or both.
- Has a history of hypersensitivity or severe allergic reaction to either telmisartan or verapamil, or any component of either licensed drug.
- Documented contraindication to taking telmisartan or verapamil: (e.g., Duchenne's muscular dystrophy, myasthenia gravis).
- Pregnant or breastfeeding.
- Participation in another current clinical trial or prior trial within the last three months.
- Urinalysis evidence of exposure to substances that may interfere with HB-1 testing (per investigator discretion).
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:トリプル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:HB-1
HB-1 fixed dose, once daily. |
HB-1 will be supplied as a dual active pharmaceutical ingredient tablet.
他の名前:
|
|
実験的:Telmisartan
Telmisartan fixed dose, once daily. |
Telmisartan will be supplied as a single active pharmaceutical ingredient tablet.
他の名前:
|
|
実験的:Verapamil
Verapamil fixed dose, once daily. |
Verapamil will be supplied as a single active pharmaceutical ingredient tablet.
他の名前:
|
|
プラセボコンパレーター:Placebo
Placebo treatment, once daily |
Matched Placebo will be supplied as a tablet.
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Number of Unexpected Panic Attacks
時間枠:Screening, Week 3, Week 4, Week 5, Week 6, Week 7, Week 8, Week 9, Week 10, Week 11, and Week 12
|
Efficacy will be evaluated through a comparison of the number of unexpected panic attack days (over the last 10 weeks in a 12-week treatment period) from Screening as compared to protocol-specified timepoints per protocol. |
Screening, Week 3, Week 4, Week 5, Week 6, Week 7, Week 8, Week 9, Week 10, Week 11, and Week 12
|
|
Incidence of Treatment-Emergent Adverse Events
時間枠:Baseline, Week 2, Week 4, Week 6, Week 8, Week 10, Week 12 and Week 13.
|
Safety will be evaluated through the monitoring of Adverse Events and the review of clinically significant changes in routine laboratory tests, ECGs, and orthostatic vital signs. |
Baseline, Week 2, Week 4, Week 6, Week 8, Week 10, Week 12 and Week 13.
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in Clinical Global Impression-Severity Scale (CGI-S)
時間枠:Baseline, Week 4, Week 8 and Week 12
|
Efficacy will be evaluated through an evaluation in Clinical Global Impression Severity scale (CGI-S) scores from Baseline as compared to protocol-specified timepoints per protocol. The Clinical Global Impression Severity Scale is rated on a 7-point scale, with the severity of illness scale using a range of responses from 1 (normal) through to 7 (amongst the most severely ill patients). |
Baseline, Week 4, Week 8 and Week 12
|
|
Change in Panic Disorder Symptom Severity Scale (PDSS)
時間枠:Screening, Week 4, Week 8 and Week 12
|
Efficacy will be evaluated through an evaluation in Panic Disorder Symptom Severity Scale (PDSS) scores from Screening as compared to protocol-specified timepoints per protocol. |
Screening, Week 4, Week 8 and Week 12
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:Prof. Malcolm Hopwood、Ramsay Clinic Albert Road
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- HB-PD-002
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。